DOI: 10.1111/eci.14292

#### META-ANALYSIS

WILEY

## Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta-analysis

Andrea Saglietto<sup>1,2,3</sup> | Giulio Falasconi<sup>3,4,5</sup> | Diego Penela<sup>3,5</sup> | Pietro Francia<sup>3,6</sup> | Arunashis Sau<sup>7,8</sup> | Fu Siong Ng<sup>7,8,9</sup> | Veronica Dusi<sup>1,2</sup> | Davide Castagno<sup>1,2</sup> | Fiorenzo Gaita<sup>2,10</sup> | Antonio Berruezo<sup>3</sup> | Gaetano Maria De Ferrari<sup>1,2</sup> | Matteo Anselmino<sup>1,2</sup>

<sup>1</sup>Division of Cardiology, Cardiovascular and Thoracic Department, "Citta della Salute e della Scienza" Hospital, Turin, Italy

<sup>2</sup>Department of Medical Sciences, University of Turin, Turin, Italy

<sup>3</sup>Heart Institute, Teknon Medical Centre, Barcelona, Spain

<sup>4</sup>Campus Clínic, University of Barcelona, Barcelona, Spain

<sup>5</sup>Arrhythmology Department, IRCCS Humanitas Research Hospital, Rozzano, Italy

<sup>6</sup>Division of Cardiology, Department of Clinical and Molecular Medicine, St. Andrea Hospital, Sapienza University

<sup>7</sup>National Heart and Lung Institute, Hammersmith Campus, Imperial College London, London, UK

<sup>8</sup>Department of Cardiology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK

<sup>9</sup>Department of Cardiology, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK

<sup>10</sup>Cardiology Unit, J Medical, Turin, Italy

#### Correspondence

Andrea Saglietto, Division of Cardiology, Cardiovascular and Thoracic Department, "Citta della Salute e della Scienza" Hospital, corso Dogliotti 14, 10126 Torino, Italy; Department of Medical Sciences, University of Turin, Italy. Email: andrea.saglietto@live.com and andrea.saglietto@unito.it

#### Abstract

**Background:** Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are new anti-hyperglycaemic drugs with proven cardiovascular (CV) benefit in diabetic and non-diabetic patients at high CV risk. Despite a neutral class effect on arrhythmia risk, data on semaglutide suggest a possible drug-specific benefit in reducing atrial fibrillation (AF) occurrence.

**Objective:** To perform a meta-analysis of randomized clinical trials (RCTs) to assess the risk of incident AF in patients treated with semaglutide compared to placebo.

**Methods and Results:** Ten RCTs were included in the analysis. Study population encompassed 12,651 patients (7285 in semaglutide and 5366 in placebo arms), with median follow-up of 68 months. A random effect meta-analytic model was adopted to pool relative risk (RR) of incident AF. Semaglutide reduces the risk of AF by 42% (RR .58, 95% CI .40–.85), with low heterogeneity across the studies ( $I^2$  0%). At subgroup analysis, no differences emerged between oral and subcutaneous

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

<sup>© 2024</sup> The Author(s). European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.

-WILEY

administration (oral: RR .53, 95% CI .23–1.24,  $I^2$  0%; subcutaneous: RR .59, 95% CI .39–.91,  $I^2$  0%; *p*-value .83). In addition, meta-regression analyses did not show any potential influence of baseline study covariates, in particular the proportion of diabetic patients (*p*-value .14) and body mass index (BMI) (*p*-value .60). **Conclusions:** Semaglutide significantly reduces the occurrence of incident AF by 42% as compared to placebo in individuals at high CV risk, mainly affected by type 2 diabetes mellitus. This effect appears to be consistent independently of the route of administration of the drug (oral or subcutaneous), the presence of underlying diabetes and BMI.

K E Y W O R D S

atrial fibrillation, glucagon-like peptide-1 receptor agonists, overweight, semaglutide

## 1 | INTRODUCTION

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are new anti-hyperglycaemic drugs which mimic the effects of the endogenous GLP-1, contributing to favourable glycaemic control and weight loss.<sup>1</sup> During the past decade, clinical trials of GLP-1 RAs mainly focused on effects on major adverse cardiovascular events (MACE) in type 2 diabetes mellitus (T2DM) patients beyond their beneficial glycaemic and weight loss effects, showing a 14% MACE reduction in T2DM patients (mostly with established cardiovascular (CV) disease).<sup>2</sup> Interestingly, the recently published SELECT trial demonstrated that semaglutide was also effective in reducing MACE in a population of overweight individuals and pre-existing CV disease without diabetes, laying the basis for its possible use in non-diabetic patients at high CV risk.<sup>3</sup>

Previous large-scale cardiovascular outcome trials (CVOTs) in diabetic patients had raised safety concerns related to an increased arrhythmic risk in patients undergoing GLP-1 RA therapy, which were allayed following results of a meta-analytic analysis demonstrating no difference in terms of atrial arrhythmias, ventricular arrhythmias, as well as sudden cardiac death, between patients on GLP-1 RA and controls.<sup>4</sup> Specific data on semaglutide suggested, instead, a potential protective effect of the drug on the incidence of atrial fibrillation (AF), a common arrhythmia known to be a major driver of morbidity and mortality.<sup>5</sup>

The aim of the present study was therefore to perform a systematic review and meta-analysis summarizing current clinical evidence and assessing the relative risk (RR) of incident AF in patients treated with semaglutide as compared to placebo.

#### 2 | METHODS

This systematic review and meta-analysis was performed in accordance to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations. $^{6}$ 

#### 2.1 | Search strategy

PubMed/MEDLINE, EMBASE, CENTRAL and ClinicalTr ial.gov databases were screened from their inceptions to 10 April 2024, using the following search strategy: "semaglutide AND (randomized OR RCT)".

# 2.2 | Study selection and quality assessment

Two investigators (AS, MA) independently reviewed the titles/abstracts and studies to determine their eligibility based on the inclusion criteria and extracted all the relevant outcomes of interest. Inclusion criteria were: (a) randomized design; (b) studies that compare semaglutide administration (oral or subcutaneous) versus placebo; and (c) studies that report incident AF episodes as adverse events. Short follow-up duration (less than 24 weeks) and non-English language were considered exclusion criteria. Risk of bias assessment was performed at the study level using the revised Cochrane risk-of-bias tool (RoB2) for RCT (Supplementary Material—Data S1).

#### 2.3 | Data extraction

Two investigators (AS and MA) extracted relevant data, which included study characteristics (study name, registration number, year of publication, population size), baseline features of participants (mean age, male proportion, baseline BMI, glycated haemoglobin [HbA1c]), semaglutide dosage and administration route, and outcome data. The primary outcome of the study was AF incidence during follow-up, while the secondary outcome was incidence of ischaemic stroke. Considered that arrhythmic events, as well as ischaemic stroke events, were commonly reported as severe adverse events (SAEs), the adverse events section of each study page on ClinicalTrials.gov was checked to collect outcome data, when present. Risk of bias at the study level was assessed using the RoB2 for RCTs<sup>7</sup> (please refer to Supplementary Appendix—Data S1).

### 2.4 Statistical analysis

Baseline features of the meta-analytic population are reported as median values between the included studies, together with their interquartile range. To account for the likely heterogeneity across studies, a random effect model (inverse-variance weighting) was adopted. Meta-analysis of RR was performed and the results with the corresponding 95% confidence interval (CI) were reported as a forest plot. Heterogeneity across studies was assessed using the Cochran *Q* test. Higgins  $I^2$  statistics was used to determine the degree of between-study heterogeneity ( $I^2 < 25\%$ —low, 25%–50%—moderate and >50%—high degree of

heterogeneity). To investigate potential publication bias, Egger test was run to identify asymmetry of funnel plot. A pre-specified subgroup analysis was also performed considering the route of administration of the drug (oral vs. subcutaneous). Finally, meta-regression analysis was performed to assess potential influence of study-specific baseline covariates and of the magnitude of body fat reduction (measured as the study-specific differential weight reduction [kg] and differential waist circumference reduction [cm] between the two treatment arms) on treatment effect for the primary outcome.

*p* values <.05 were considered statistically significant. Statistical analyses were performed with RStudio version 1.3.959 (Posit PBC, Boston, USA).

## 3 | RESULTS

Initial search retrieved 2974 results (please refer to Figure 1 for the PRISMA flow diagram). Forty reports were assessed for eligibility and 10 of them finally included in the present systematic review and meta-analysis.<sup>8-17</sup> Figure S1 reports study quality evaluation through RoB2 tool, showing that the majority of included RCTs were




FIGURE 1 Flow chart of the search strategy following PRISMA guidelines.

#### 4 of 10 | WILEY

judged at low risk of bias. Table 1 reports main clinical characteristics of the included studies.

The final study population encompassed 12,651 patients (7285 in the semaglutide and 5366 in the placebo arm, respectively), with a nearly 1:1 male-to-female ratio (males 51% [IQR 45–63]). Median age was 56 years (IQR 51–66 years), while median body mass index (BMI) and glycosylated haemoglobin (HbA1c) were, respectively 33 kg/  $m^2$  (IQR 32–36 kg/m<sup>2</sup>) and 8% (IQR 6.2–8.1%). Median follow-up duration was 68 months (IQR 52–68 months). Concerning drug administration route, four studies used oral semaglutide as the intervention arm (total number of patients: 4194), while the remaining six studies used subcutaneous semaglutide (total number of patients: 8457). Pooled incidence rate of AF episodes in the control arm was .86 events per 100 person-years (Figure S2).

Meta-analysis revealed that semaglutide reduces the risk of incident AF episodes by 42% (RR .58, 95% CI .40-.85), with low heterogeneity across the included studies ( $I^2$  0%). The pre-specified subgroup analysis based on administration route did not report any significant difference between oral and subcutaneous (oral semaglutide: RR .53, 95% CI .23–1.24,  $J^2$  0%; subcutaneous semaglutide: RR .59, 95% CI .39–.91,  $I^2$  0%; p-value for subgroup differences: .83). Figure 2 displays the meta-analytic forest plot, reporting overall and subgroup (oral and subcutaneous) treatment effect estimates. Funnel plot analysis (Figure S3) did not detect potential risk for publication bias (Egger's test *p*-value: .71). Concerning secondary outcome, for which data was available in 7 out of the 10 included studies, no significant difference emerged between study arms (RR .76, 95% CI .47–1.24, I<sup>2</sup> 0%; Figure 3). Moreover, at sensitivity analysis by multivariate meta-analytic approach including both outcomes into the model, results were similar to those of the univariate models separately evaluating primary and secondary outcome (Table S1).

Meta-regression analyses for the primary outcome did not show any potential influence of the following baseline study covariates (Figure 4): follow-up duration (*p*-value .42), male sex (*p*-value .72), age (*p*-value .71), proportion of T2DM patients in each study (*p*-value .14), BMI (*p*-value .60), Hb1AC (*p*-value .49). Similarly, treatment effect appeared to be independent from the achieved magnitude of differential body fat reduction (differential body weight reduction: *p*-value .63; differential waist circumference reduction: *p*-value .15). Table S2 reports studyspecific body fat reduction metrics.

### 4 | DISCUSSION

The main findings of the present systematic review and meta-analysis (Graphical Abstract) are:

- in a meta-analytic population constituted by overweight individuals mainly affected by T2DM GLP-1 RA semaglutide significantly reduces the occurrence of incident AF episodes (-42%) along a median follow-up of 68 months;
- 2. the meta-analytic estimate did not show heterogeneity across the included RCTs ( $I^2 0\%$ );
- 3. the reduction in incident AF episodes appears to be independent from the administration route of the drug (oral vs. subcutaneous); and
- 4. baseline clinical variables, as well as the magnitude of fat reduction, did not influence the extent of drug effect; notably the treatment effect appeared to be independent from BMI and presence of T2DM.

In the past few years, obesity has clearly emerged as an independent risk factor for the development of AF, as documented by an additional 25% risk of incident AF for every five-unit increase in BMI.<sup>18,19</sup> Moreover, scientific evidence has accumulated demonstrating how excessive body weight is related to sub-optimal results of AF catheter ablation and how weight loss, in a dose-dependent fashion, reduces long-term recurrences after ablation and AF severity and burden in unselected cohort of AF patients.<sup>20–24</sup>


Different mechanisms have been proposed to explain how overweight/obesity contribute to risk, progression and severity of AF.<sup>25,26</sup> Obesity might be closely related to systemic conditions such as hypertension, obstructive sleep apnoea syndrome, diabetes, as well as might involve an increased local epicardial<sup>27,28</sup> and intramyocardial<sup>29,30</sup> fat content. Additionally, in obese individuals, the white adipose tissue (WAT), that includes the epicardial adipose tissue, undergoes profound changes; it expands, becomes dysfunctional and develops a low-grade inflammatory state.<sup>31</sup> These systemic and local changes in turn promote inflammation and oxidative stress, potentially leading to structural remodelling, left atrial enlargement and electrical remodelling, ultimately causing and perpetuating AF. Interestingly enough, activating the thermogenic brown adipose tissue (BAT) and browning of WAT are both under active study as appealing therapeutic interventions for the prevention and re-versal of obesity; GLP-1 mediated pathways (central and peripheral) are actively involved in this process.32

Among the different GLP-1 RAs, semaglutide was shown to have the highest efficacy in reducing body weight.<sup>33</sup> This is most likely due to an additional direct effect on the arcuate nucleus of the hypothalamus, affecting the activity of neural pathways involved in food intake, reward and energy expenditure, including centrally mediated BAT activation and promotion of WAT browning.<sup>34,35</sup> This peculiarity might explain why semaglutide,

| DIONEER4 2019 NCT02863419 TDM 427 <sup>4</sup> 285 142 100 52   PIONEER5 2019 NCT02827708 TDM and<br>moderate renal<br>moderate renal<br>moderate renal 324 163 101 63   PIONEER5 2019 NCT02827708 TDM much<br>moderate renal 318 163 100 641   PIONEER11 2021 NCT0410547 TDM with high 318 1591 100 653   PIONEER11 2023 NCT0410547 TDM 521 390 1310 103 653 653 653 653 653   SUSTAIN6 2016 NCT012046 TDM 3297 1649 100 653 <t< th=""><th>PopulationSemaglutidePlacebo(n)arm (n)arm (n)</th><th>MICT 01</th><th>(%)</th><th>Age BMI<br/>(years) (kg/1</th><th>like (kg/m<sup>2</sup>) (%)</th><th>Follow-up<br/>(months)</th><th>Administration</th><th>Dosage</th></t<> | PopulationSemaglutidePlacebo(n)arm (n)arm (n) | MICT 01 | (%) | Age BMI<br>(years) (kg/1 | like (kg/m <sup>2</sup> ) (%) | Follow-up<br>(months) | Administration | Dosage               |
|--|---|---------|-----|--------------------------|-------------------------------|-----------------------|----------------|----------------------|
| <b>ERF</b> 3 <b>010</b> NCT02827708 T2DM and<br>moderate renal<br>impairment <b>324 163 161 100 ERF</b> 1 <b>2019</b> NCT02692716 T2DM with high <b>3182 1591 1591 100 ERF</b> 1 <b>2023</b> NCT04109547 T2DM <b>521 390 131 100 HIV6 2016</b> NCT01720446 T2DM <b>521 390 131 100 4IV6 2016</b> NCT0173548935 Overweight or <b>101 100 100 1 2021</b> NCT03548935 Overweight or <b>1901 1306 655 0 1 2021</b> NCT03548935 Overweight or <b>100 100 100 100 2 2 101 100 100 101 106 100 1 2 101 100 101 101 101 101 101 1 1 1 1 1</b>  |   | 100     |     | 56 33                    | 8                             | 52                    | Oral           | 14 mg daily          |
| EEK 0 2019 NCT02692716 T2DM with high 0 3182 1591 100   EFK 1 2023 NCT04109547 T2DM 521 390 131 100   HM 6 2016 NCT01720446 T2DM 3297 1649 100   Image: Not 10075493 Overweight of 100 3297 1649 100 100   Image: Not 10075493 Overweight of 100 3297 1649 100 100   Image: Not 10075493 Overweight of 100 1961 1306 655 0   Image: Not 10075493 Overweight of 100 1306 655 0 0   Image: Not 10075403 Overweight of 100 100 100 0 0   Image: Not 1007540383 Overweight of 100 100 203 0 0   Image: Not 1007540383 Overweight of 100 203 0 0 0   Image: Not 10075403831 Image: Not 10075403831 100 203 101 253   Image: Not 10075403831 Image: Not 100  |   | 100     |     | 70 32.4                  | ∞                             | 26                    | Oral           | 14 mg daily          |
| EEK 11 2021 NCT04109547 T2DM 521 300 131 100   4IV6 2016 NCT01720446 T2DM 3297 1648 1649 100   1 2021 NCT03548935 Overweightor 1961 1306 655 0   1 2021 NCT03552757 T2DM 805 402 100   2 2021 NCT03552757 T2DM, overweight 1207 805 402 100   2 2021 NCT03552757 T2DM, overweight 1207 805 402 100   4 2021 NCT03552757 T2DM, overweight 1207 805 535 268 0   6 2021 NCT0354897 Overweight or 803 535 268 0   6 2021 NCT0354897 Overweight or 209 101 25   6 2021 NCT0381157 Overweight or 209 101 25   6 2023 <t< td=""><td></td><td>100</td><td></td><td>66 32.3</td><td>3 8.2</td><td>68</td><td>Oral</td><td>14 mg daily</td></t<>   |   | 100     |     | 66 32.3                  | 3 8.2                         | 68                    | Oral           | 14 mg daily          |
| 4IV6 2016 NCT0172046 T2DM 327 1648 1649 100   1 2021 NCT03548935 Overweight of<br>t2DM 1961 1306 655 0   2 2021 NCT03552757 DAL, overweight 1207 805 402 100   2 2021 NCT03552757 T2DM, overweight 1207 805 402 100   4 2021 NCT03548987 Overweight of<br>to obsee 803 535 268 0   6 2021 NCT0351574 Overweight of<br>to obsee, vor 72DM 803 535 268 0   6 2022 NCT03811574 Overweight of<br>to bese, possible 400 299 101 25   6 2023 NCT04788511 EVEF >45%, 529 268 0   6 2023 NCT04788511 203 269 0 25  |   | 100     |     | 52 n.r.                  | n.r.                          | 26                    | Oral           | 3/7/14mg<br>daily    |
| 1 2021 NCT03548935 Overweight of<br>obes, without 1961 1306 655 0   2 2021 NCT03552757 T2DM, 805 402 100   4 2021 NCT03558757 T2DM, overweight 1207 805 402 100   4 2021 NCT03548987 Overweight or<br>obes, w/o T2DM 803 535 268 0   6 2022 NCT03811574 Overweight or<br>obes, w/o T2DM 400 299 101 255   6 2023 NCT04788311 LVEF >45%, 529 569 0 0   6 2023 NCT04788311 LVEF >45%, 529 263 0 0  |   | 100     |     | 64,6 32.8                | 8 8.7                         | 104                   | Subcutaneous   | 5/1 mg<br>weekly     |
| 2 2021 NCT0352757 T2DM, overweight 1207 805 402 100   4 2021 NCT03548987 orobese 803 535 268 0   6 2021 NCT03548987 Overweight or<br>obese, w/o T2DM 803 535 268 0   6 2022 NCT03811574 Overweight or<br>obese, possible 400 299 101 25   7 2023 NCT04788511 LVEF >45%, 529 263 0   7 2023 NCT04788511 LVEF >45%, 529 263 0  |   | 0       |     | 46 37.8                  | 8 5.7                         | 68                    | Subcutaneous   | 2.4 mg weekly        |
| 4 2021 NCT03548987 Overweight or<br>obese, w/o T2DM 803 535 268 0   6 2022 NCT03811574 Overweight or<br>obese, possible 400 299 101 25   7 72DM Overweight or<br>obese, possible 400 299 101 25   7 2023 NCT04788511 LVEF >45%, 529 529 263 0   F NYHA class II-IV, NYHA class II-IV, 529 263 0  |   | 100     |     | 55 35.7                  | 7 8.1                         | 68                    | Subcutaneous   | 1/2.4 mg<br>weekly   |
| 6 2022 NCT03811574 Overweightor 400 299 101 25<br>obese, possible<br>T2DM<br>2023 NCT04788511 LVEF >45%, 529 263 266 0<br>F<br>NYHA class II-IV,   |   | 0       |     | 46 34.1                  | 1 5.4                         | 68                    | Subcutaneous   | 2.4 mg weekly        |
| 2023 NCT04788511 LVEF >45%, 529 263 266 0<br>F NYHA class II-IV,   |   | 25      |     | 51 31.9                  | 9 6.4                         | 68                    | Subcutaneous   | 1.7/2.4 mg<br>weekly |
| no T2DM  |   | 0       |     | 69 37                    | n.r.                          | 52                    | Subcutaneous   | 2.4 mg weekly        |


TABLE 1 Details of the studies included in the present systematic review and meta-analysis.


SAGLIETTO ET AL.



Residual heterogeneity:  $Tau^2 = NA$ ;  $Chi^2 = 5.15$ , df = 8 (P = 0.74);  $I^2 = 0\%$ Test for subaroup differences:  $Chi^2 = 0.05$ . df = 1 (P = 0.83)

FIGURE 2 Forest plot for AF occurrence comparing semaglutide vs placebo arms, also providing the estimates for subgroups based on drug administration route (oral or subcutaneous).





differently to other GLP-1 RAs appearing neutral in terms of risk of incident AF, reduces the risk of AF in overweight individuals. It should also be kept in mind that semaglutide is the only GLP-1 RA with an oral formulation available, potentially reaching similar pharmacological effects with a greater compliance. Of note, it should be highlighted that semaglutide has shown more effective in improving metabolic status than the other GLP-1 RAs,<sup>36</sup> and this






FIGURE 4 Meta-regression bubble plots for study-level clinical features and body fat reduction metrics.

WILEY

peculiarity might be one of the potential players, adjunctive to weight loss, of the AF protection effect. The relevance of metabolic status has been thoroughly discussed over recent years, particularly because it has been used to explain, at least partly, the so-called 'obesity paradox' the phenomenon whereby overweight and mildly obese patients with established CV disease have apparently better short- and moderate-term prognoses compared with leaner patients—also claimed for AF patients.<sup>37,38</sup> Likely, it is rather the complex interplay between adipose tissue (only grossly described by BMI, not able to discriminate between subcutaneous and visceral fat) and metabolic status that determines the CV risk of a specific individual.

Interestingly, since no significant association between the percentage of diabetic patients of the included studies and the meta-analytic risk estimate emerged, the present results suggest that drug effect is likely maintained in non-diabetic individuals. The target population for the drug might therefore be larger than the diabetic population. Of note, one of the included studies, the STEP HFpEF trial, enrolled a population of overweight patients without T2DM and with heart failure with preserved ejection fraction, demonstrating that in a higher AF risk population (incidence rate of AF was higher compared to that in cohorts of non-HF patients with T2DM, please refer to Figure S2) semaglutide has high efficacy in preventing incident AF episodes (study-specific treatment estimate: RR .25 [95 CI .07-.89]). This translates into a study-specific NNT to prevent an AF episode of 30 (at 1 year), compared to an overall meta-analytic NNT of 357. Albeit the overall meta-analytic population was characterized by low risk of incident AF (incidence rate of .86 per 100 person-year) and resulted in a relatively high NNT, the effect appears to be consistent (and, at least numerically, potentially stronger) in a higher-risk subpopulation, such as that of STEP-HFpEF (incidence rate of 4.25 per 100 person-year). Altogether, these findings provide interesting potential clinical applications, such as considering to prescribe semaglutide in T2DM or overweight individuals without known AF to reduce the risk of experiencing the arrhythmia and its potential consequences. No statistically significant differences were found in ischaemic stroke occurrences between semaglutide and placebo group, however secondary outcome analysis is limited by a very low incidence rate of the outcome, not permitting adequate power and therefore not excluding that in higher risk populations these differences could have reached statistical significance also for ischaemic stroke, the most feared AF consequence. Future specifically designed clinical trials are needed to support the potential use of semaglutide as a new upstream therapy for preventing AF in T2DM and/or overweight individuals, particularly assessing how to select patients who will benefit most from the drug in terms of AF prevention.

Finally, despite the meta-regression analyses not showing a relationship between absolute weight reduction and treatment effect, the magnitude of differential body fat reduction showed a trend, albeit not statistically significant, of an increased treatment effect when a higher reduction in waist circumference was achieved, potentially suggesting that a key driver in reducing AF risk is central obesity (visceral adipose tissue). Closing the circle, visceral adiposity has been associated with epicardial adipose tissue inflammation and dysfunction, both involved in AF promotion.<sup>39</sup> Of note, a recent study performing Mendelian randomization analysis showed that genetically determined central obesity, as denoted by waist circumference, hip circumference and trunk fat mass, was associated with an increased risk of AF.<sup>40</sup> This association still remained significant even after adjusting for potential mediators such as hypertension, diabetes, BMI, body fat percentage and sleep apnea.

#### 4.1 | Limitations

There are some limitations to our systematic review and meta-analysis. First, AF episodes reported as SAE in the included trials are likely clinically relevant symptomatic episodes, thus virtually excluding possible asymptomatic episodes that could have been detected in dedicated trials implementing ad-hoc monitoring strategies to assess AF occurrence (e.g. periodic ECG Holter monitoring). Second, due to the limited number of included studies and that some studies provided limited contribution to the pooled estimates, we cannot exclude that meta-regression analyses were underpowered to detect potential significant causes of heterogeneity among the baseline clinical covariates. Moreover, even though we did not apparently detect heterogeneity across studies, we cannot exclude that the computed  $I^2$  index might be due to the low number of events in the majority of the studies, rather than indicating a real absence of heterogeneity of the investigated outcomes. Finally, the lack of a deeper cardiac phenotyping of the included patients prevents from being able to perform specific meta-regression analysis based on specific cardiological features (e.g. left ventricular ejection fraction, baseline prevalence of AF).

## 5 | CONCLUSION

The GLP-1 RA semaglutide significantly reduces the occurrence of incident AF episodes by 42% as compared to placebo in overweight individuals mainly affected by T2DM; this effect appears to be consistent across the different randomized trials included in the present study and independent of (1) the administration route of the drug (oral or subcutaneous), (2) the presence of underlying T2DM, and (3) BMI. Altogether, these findings potentially lay the basis for broadening the use of the drug in overweight individuals, even without a concomitant diagnosis of diabetes, to reduce the risk of incident AF. Future dedicated trials should be designed to address this hypothesis.

#### AUTHOR CONTRIBUTIONS

A.Saglietto and M.A. designed the study. A.Saglietto, G.F., D.P., P.F. retrieved the studies. A.Saglietto performed the analysis. All the authors (A.Saglietto, G.F., D.P., P.F., A.Sau, F.S.N., V.D., D.C., F.G., A.B., G.M.D.F. and M.A.) critically analysed the results of the analysis. All the authors (A.Saglietto, G.F., D.P., P.F., A.Sau, F.S.N., V.D., D.C., F.G., A.B., G.M.D.F. and M.A.) wrote the manuscript and approved its submission.

#### ACKNOWLEDGEMENTS

Open access publishing facilitated by Universita degli Studi di Torino, as part of the Wiley - CRUI-CARE agreement.

#### CONFLICT OF INTEREST STATEMENT

The authors declare no conflicts of interest.

#### DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

#### ORCID

Andrea Saglietto D https://orcid. org/0000-0001-9475-1507

#### REFERENCES

- 1. Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. *Nat Rev Cardiol.* 2023;20:463-474.
- Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. *Lancet Diabetes Endocrinol*. 2021;9:653-662.
- 3. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. *N Engl J Med*. 2023;389:2221-2232.
- 4. Wu S, Lu W, Chen Z, Dai Y, Chen K, Zhang S. Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials. *Diabetol Metab Syndr.* 2022;14:195.
- Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European. *Eur Heart J.* 2021;42:373-498.

- 6. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ*. 2009;339:b2700.
- Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ*. 2019;366:14898.
- Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. *Lancet.* 2019;394:39-50.
- Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. *Lancet Diabetes Endocrinol*. 2019;7:515-527.
- Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381:841-851.
- 11. Wang W, Chen R, Davies AL, et al. PIONEER 11: efficacy and safety of oral semaglutide versus placebo in predominantly Chinese patients with T2D treated with diet and exercise. *Diabetes Res Clin Pract.* 2023;197:110316.
- Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2016;375:1834-1844.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly Semaglutide in adults with overweight or obesity. *N Engl J Med.* 2021;384:989-1002.
- 14. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. *Lancet.* 2021;397:971-984.
- 15. Kadowaki T, Isendahl J, Khalid U, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. *Lancet Diabetes Endocrinol.* 2022;10:193-206.
- Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous Semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. *JAMA*. 2021;325:141-1425.
- 17. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. *N Engl J Med.* 2023;389:1069-1084.
- Wong CX, Sullivan T, Sun MT, et al. Obesity and the risk of incident, post-operative, and post-ablation atrial fibrillation: a meta-analysis of 626,603 individuals in 51 studies. *JACC Clin Electrophysiol.* 2015;1:139-152.
- Patel KHK, Reddy RK, Sau A, Sivanandarajah P, Ardissino M, Ng FS. Obesity as a risk factor for cardiac arrhythmias. *BMJ Med.* 2022;1:e000308.
- Lavie CJ, Pandey A, Lau DH, Alpert MA, Sanders P. Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis: effects of weight loss and exercise. *J Am Coll Cardiol.* 2017;70:2022-2035.
- 21. Saglietto A, Gaita F, Blomstrom-Lundqvist C, et al. AFA-recur: an ESC EORP AFA-LT registry machine-learning web calculator predicting atrial fibrillation recurrence after ablation. *Europace*. 2023;25:92-100.
- 22. Pathak RK, Middeldorp ME, Meredith M, et al. Long-term effect of goal-directed weight management in an atrial fibrillation

10 of 10 | WILEY

cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol. 2015;65:2159-2169.

- 23. Mulder MJ, Kemme MJB, Allaart CP. Radiofrequency ablation to achieve durable pulmonary vein isolation. *Europace*. 2022;24:874-886.
- 24. Lee G, Baker E, Collins R, Merino JL, Desteghe L, Heidbuchel H. The challenge of managing multimorbid atrial fibrillation: a pan-European European heart rhythm association (EHRA) member survey of current management practices and clinical priorities. *Europace*. 2022;24:2004-2014.
- 25. Shu H, Cheng J, Li N, et al. Obesity and atrial fibrillation: a narrative review from arrhythmogenic mechanisms to clinical significance. *Cardiovasc Diabetol.* 2023;22:192.
- Ardissino M, Patel KHK, Rayes B, Reddy RK, Mellor GJ, Ng FS. Multiple anthropometric measures and proarrhythmic 12-lead ECG indices: a mendelian randomization study. *PLoS Med.* 2023;20:e1004275.
- Ernault AC, Meijborg VMF, Coronel R. Modulation of cardiac arrhythmogenesis by epicardial adipose tissue: JACC state-ofthe-art review. JAm Coll Cardiol. 2021;78:1730-1745.
- 28. Ballatore A, Gatti M, Mella S, et al. Epicardial atrial fat at cardiac magnetic resonance imaging and AF recurrence after transcatheter ablation. *J Cardiovasc Dev Dis*. 2024;11:137.
- 29. Saglietto A, Falasconi G, Soto-Iglesias D, et al. Assessing left atrial intramyocardial fat infiltration from computerized tomography angiography in patients with atrial fibrillation. *Europace*. 2023;25:euad351.
- 30. Frea S, Andreis A, Scarlatta V, et al. Subclinical left ventricular dysfunction in severe obesity and reverse cardiac remodeling after bariatric surgery. *J Cardiovasc Echogr.* 2020;30:22-28.
- Liu X, Zhang Z, Song Y, Xie H, Dong M. An update on brown adipose tissue and obesity intervention: function, regulation and therapeutic implications. *Front Endocrinol*. 2023;13:1065263.
- 32. Beiroa D, Imbernon M, Gallego R, et al. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. *Diabetes*. 2014;63:3346-3358.
- Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. *Mol Metab.* 2021;46:46.
- Gabery S, Salinas CG, Paulsen SJ, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. *JCI Insight*. 2020;5:e133429.

- 35. Lee SJ, Sanchez-Watts G, Krieger JP, et al. Loss of dorsomedial hypothalamic GLP-1 signaling reduces BAT thermogenesis and increases adiposity. *Mol Metab.* 2018;11:33-46.
- 36. Patoulias D, Popovic DS, Stoian AP, Janez A, Sahebkar A, Rizzo M. Effect of semaglutide versus other glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors in patients with type 2 diabetes: a systematic review and meta-analysis of head-to-head, phase 3, randomized controlled trials. *J Diabetes Complications*. 2023;37:108529.
- 37. Zhao M, Du W, Zhao Q, et al. Transition of metabolic phenotypes and risk of atrial fibrillation according to BMI: kailuan study. *Front Cardiovasc Med.* 2022;9:888062.
- Corica B, Romiti GF, Proietti M, et al. Clinical outcomes in metabolically healthy and unhealthy obese and overweight patients with atrial fibrillation: findings from the GLORIA-AF registry. *Mayo Clin Proc.* 2024;99:927-939.
- Poggi AL, Gaborit B, Schindler TH, Liberale L, Montecucco F, Carbone F. Epicardial fat and atrial fibrillation: the perils of atrial failure. *Europace*. 2022;24:1201-1212.
- 40. Deng Y, Li L, Li Q, et al. Central obesity as a potential causal risk factor for atrial fibrillation: evidence from Mendelian randomization study. *Europace*. 2024;26:euae061.

#### SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Saglietto A, Falasconi G, Penela D, et al. Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta-analysis. *Eur J Clin Invest.* 2024;00:e14292. doi:10.1111/ eci.14292